絞り込み

16645

広告

Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience.

著者 Rossi S , Finocchiaro G , Toschi L , Santoro A
Immunotherapy.2019 Jun 14 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (5view , 0users)

Full Text Sources

Immunotherapy opened new frontiers in metastatic non-small-cell lung cancer treatment, but not all patients benefit from it. We retrospectively evaluated 65 metastatic non-small-cell lung cancer patients, treated with nivolumab, considering as disadvantaged subgroups those with poor performance status, elderly, patients with brain metastases at baseline, with high disease burden and refractory to platinum. No differences in overall survival or time to treatment failure were found according to performance status, age, presence of brain metastases at baseline or high disease burden. Conversely, patients refractory to platinum had a statistically significant shorter overall survival and time to treatment failure. At multivariate analysis only platinum resistance was confirmed as an independent predictive factor. Our study suggests that only refractoriness to platinum salts influence the efficacy of nivolumab.
PMID: 31199183 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード